A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Key Inclusion Criteria:

- Willing and able to provide written informed consent

- Have either previously participated in a Gilead-sponsored HCV study and received a
sofosbuvir-containing regimen without interferon OR at pre-selected sites only, have
received an all-oral SOF-based regimen outside a clinical study. These individuals
must have documentation of the regimen, start and end of treatment dates (month and
year), and of having achieved SVR12.

- Have achieved SVR either in a Gilead-sponsored study, as defined in the treatment
protocol OR for individuals who enroll after receiving an all-oral SOF-based regimen
outside a clinical study, SVR will be defined as HCV RNA < LLOQ approximately 12 weeks
following last dose of treatment.

- Have liver cirrhosis, as defined in the treatment protocol, and have not had a liver
transplant after receiving a SOF-containing regimen OR individuals who enroll after
receiving an all-oral SOF-based regimen outside a clinical study, will have had
cirrhosis confirmed prior to initiation of HCV treatment.

Key Exclusion Criteria:

- Individuals planning to initiate a new course of HCV therapy, including approved
products and any investigational agents, during the course of this Registry

- History of clinically-significant illness or any other major medical disorder that may
interfere with the follow-up, assessments, or compliance with the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.